Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic and nutritional product potential of the gut-brain axis. The company integrates cutting-edge technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics and products that improve human health and nutrition. The company's founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D. and Nobel laureate Richard Axel, M.D. Headquartered at the Alexandria Center® for Life Science in New York City, the company's founding investors include Lux Capital, Polaris Partners and The Column Group.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
12/13/15	$44,000,000	Series A	Alexandria Venture Investments Column Group Illumina, Inc Lux Capital Polaris Partners	undisclosed
02/22/18	$66,000,000	Series B	Alexandria Venture Investments Illumina Ventures Lux Capital Polaris Partners The Column Group Two Sigma Ventures	undisclosed
12/05/18	$21,000,000	Series B Extension	Alexandria Real Estate Equities Bill Gates Illumina Ventures Lux Capital Polaris Partners The Column Group Two Sigma Ventures	undisclosed
03/25/20	$112,000,000	Series C	Alexandria Venture Investments Bill Gates Casdin Capital Euclidean Capital Illumina Ventures Lux Capital Polaris Partners The Column Group Two Sigma Ventures	undisclosed
02/15/22	$236,000,000	Series D	Mubadala Investment Company The Column Group	undisclosed